Department of Medicine, Harvard Medical School, 250 Longwood Avenue, Boston, MA 02115, USA.
Hematol Oncol Clin North Am. 2013 Aug;27(4):829-41, ix. doi: 10.1016/j.hoc.2013.05.011.
The costs of breast cancer care are substantial and growing, and they extend across the spectrum of care. Medical therapies and hospitalizations account for a significant proportion of these costs. Cost-effectiveness analysis (CEA) is the preferred method for assessing the health benefits of medical interventions relative to their costs. Although many CEAs have been conducted for a wide range of breast cancer treatments, these analyses are not used routinely to guide coverage or utilization decisions in the United States. Currently, patients and providers may not consider costs when making most treatment decisions; this is likely to change as payment reform spreads.
乳腺癌治疗的费用是巨大且不断增长的，并且贯穿整个治疗过程。医疗疗法和住院治疗占这些费用的很大一部分。成本效益分析（CEA）是评估医疗干预相对于其成本的健康效益的首选方法。尽管已经针对各种乳腺癌治疗方法进行了许多 CEA，但这些分析在美国并未常规用于指导覆盖范围或利用决策。目前，在做出大多数治疗决策时，患者和提供者可能不会考虑成本；随着支付方式改革的普及，这种情况可能会发生变化。
